You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 47 No. 8, August 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Secretion and Clinical Significance of Atrial Natriuretic Peptide in Patients With Muscular Dystrophy

Hisaomi Kawai, MD; Katsuhito Adachi, MD; Chiyomi Kimura, MD; Takeshi Nishiuchi, MD; Yasuhiro Yamasaki, MD; Yoshihiko Tsutsui, MD; Shiro Saito, MD

Arch Neurol. 1990;47(8):900-904.


Abstract

• The plasma concentration of atrial natriuretic peptide was measured in patients with muscular dystrophies to study its relationship with congestive heart failure. In patients with Duchenne muscular dystrophy, the plasma atrial natriuretic peptide concentration was 35.5 ± 3.3 pg/mL (mean ± SE), which was higher than that in age-matched normal subjects (9.8 ± 0.6 pg/mL). It increased with progression of disability and showed significant correlations with the cardiothoracic ratio and the ratio of the preejection period to the left ventricular ejection time. In patients with other types of muscular dystrophy, the plasma atrial natriuretic peptide concentration showed no significant change. Immunohistochemical examination demonstrated many atrial natriuretic peptide-positive cells in atrial muscle of an autopsied patient, indicating preservation of the peptide until the end stage. These findings suggest that measurement of the plasma atrial natriuretic peptide concentration is useful for evaluating heart failure in patients with Duchenne muscular dystrophy.



Author Affiliations

From the First Department of Internal Medicine, School of Medicine, The University of Tokushima (Japan) (Drs Kawai, Nishiuchi, Yamasaki, Tsutsui, and Saito), and the Department of Internal Medicine, Tokushima Hospital of National Sanatorium (Drs Adachi and Kimura).


Footnotes

Accepted for publication November 3, 1989.

Reprint requests to First Department of Internal Medicine, School of Medicine, The University of Tokushima, Kuramoto-3, Tokushima 770, Japan (Dr Kawai).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Assessment of Cardiac Function in Adolescents With Duchenne Muscular Dystrophy: Importance of Neurohormones
Ramaciotti et al.
J Child Neurol 2002;17:191-194.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.